BCL11B
BCL11B (BCL11 transcription factor B, also known as CTIP2, CTIP-2, hRIT1-alpha, SMARCM2 and ZNF856B) is a nuclear C2H2-type zinc finger transcription factor. It regulates the differentiation and survival of T-lymphocytes during thymocyte development. Browse Assay Genie's current range of BCL11B research reagents below, or read on for the biology behind the target.
BCL11B is a key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. It also helps control how responsive haematopoietic stem cells are to chemotactic signals, by modulating expression of the receptors CCR7 and CCR9, which direct progenitor cells from the bone marrow to the thymus. In activated CD4(+) T-lymphocytes, it regulates the IL2 promoter and enhances IL2 expression.
The BCL11B gene encodes a C2H2-type zinc finger protein that is a transcriptional repressor. It represses transcription through direct binding to a GC-rich response element, independently of TFCOUP2. The protein is regulated by the NuRD nucleosome remodelling and histone deacetylase complex. HGNC places it in the C2H2-type zinc finger group and among the BAF complex subunits. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. The mouse ortholog is Bcl11b.
BCL11B is closely related to BCL11A, a gene whose translocation may be associated with B-cell malignancies. BCL11B itself is described as a tumour suppressor and may also function in the P53-signalling pathway. Earlier gene names include B-cell CLL/lymphoma 11B (zinc finger protein) and BAF chromatin remodelling complex subunit BCL11B. Researchers studying BCL11B often use a BCL11B antibody, BCL11B ELISA kit or BCL11B protein reagent to examine its role in T-cell biology and transcriptional control.
BCL11B regulates the differentiation and survival of T-lymphocytes during thymocyte development, making it central to studies of T-cell lineage programming.
It modulates CCR7 and CCR9 expression, which direct progenitor cells from the bone marrow to the thymus.
BCL11B represses transcription via a GC-rich response element and is regulated by the NuRD complex, linking it to chromatin remodelling.
BCL11B acts as a tumour suppressor and may function in P53 signalling, relevant to cancer and lymphoid malignancy research.
BCL11B is a transcription factor that regulates differentiation and survival of T-lymphocytes during thymocyte development. It controls CCR7 and CCR9 expression in haematopoietic stem cells, enhances IL2 expression in activated CD4(+) T-lymphocytes, and represses transcription by binding a GC-rich response element.
BCL11B is also called CTIP2, CTIP-2, hRIT1-alpha, SMARCM2 and ZNF856B. Its UniProt name is B-cell lymphoma/leukaemia 11B. NCBI Gene reports four alternatively spliced transcript variants that encode distinct isoforms.
BCL11B is closely related to BCL11A, whose translocation may be associated with B-cell malignancies. BCL11B is described as a tumour suppressor and may act in P53 signalling. The mouse ortholog is Bcl11b; check the datasheet of any product for its validated reactivity.
Other BCL family members and the closely related BCL11A, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9C0K0; product specifications from Assay Genie datasheets.